1. Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012;87(10):982-990. doi:10.1016/j.mayocp.2012.04.017
2. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021-1026. doi:10.1001/archinte.166.9.1021
3. Wang J, Jiang F, Yating Y, et al. Off-label use of antipsychotic medications in psychiatric inpatients in China: a national real-world survey. BMC Psychiatry. 2021;21(1):375. doi:10.1186/s12888-021-03374-0
4. Chen H, Reeves JH, Fincham JE, et al. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psychiatry. 2006;67(6):972-982. doi:10.4088/jcp.v67n0615
5. Ventola CL. Off-label drug information: regulation, distribution, evaluation, and related controversies. P T. 2009;34(8):428-440.
6. Anton RF, Latham P, Voronin K, et al. Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med. 2020;180(5):728-736. doi:10.1001/jamainternmed.2020.0249
7. Kranzler HR, Feinn R, Morris P, et al. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction. 2019;114(9):1547-1555. doi:10.1111/add.14655
8. Mason BJ, Quello S, Goodell V. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(1):70-77. doi:10.1001/jamainternmed.2013.11950
9. Fariba KA. Saadabadi A. Topiramate. StatPearls [Internet]. StatPearls Publishing LLC; 2023. Accessed December 22, 2022. https://www.ncbi.nlm.nih.gov/books/NBK554530/
10. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677-1685. doi:10.1016/S0140-6736(03)13370-3
11. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641-1651. doi:10.1001/jama.298.14.1641
12. Knapp CM, Ciraulo DA, Sarid-Segal O, et al. Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol. 2015;35(1):34-42. doi:10.1097/JCP.0000000000000246
13. Kranzler HR, Covault J, Feinn R, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014;171(4):445-452. doi:10.1176/appi.ajp.2013.13081014
14. Blodgett JC, Del Re AC, Maisel NC, et al. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38(6):1481-1488. doi:10.1111/acer.12411
15. Paparrigopoulos T, Tzavellas E, Karaiskos D, et al. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry. 2011;11:41. doi:10.1186/1471-244X-11-41
16. Tang YL, Hao W, Leggio L. Treatments for alcohol-related disorders in China: a developing story. Alcohol Alcohol. 2012;47(5):563-570. doi:10.1093/alcalc/ags066
17. Pierce M, Sutterland A, Beraha EM, et al. Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2018;28(7):795-806. doi:10.1016/j.euroneuro.2018.03.017
18. Andrade C. Individualized, high-dose baclofen for reduction in alcohol intake in persons with high levels of consumption. J Clin Psychiatry. 2020;81(4):20f13606. doi:10.4088/JCP.20f13606
19. Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association Practice Guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175(1):86-90. doi:10.1176/appi.ajp.2017.1750101
20. Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889-1900. doi:10.1001/jama.2014.3628
21. US Department of Veterans Affairs, US Department of Defense. Management of Substance Use Disorder (SUD) (2021). US Department of Veterans Affairs. 2021. Accessed December 24, 2022. https://www.healthquality.va.gov/guidelines/mh/sud/
22. Potenza MN, Balodis IM, Derevensky J, et al. Gambling disorder. Nat Rev Dis Primers. 2019;5(1):51. doi:10.1038/s41572-019-0099-7
23. Lupi M, Martinotti G, Acciavatti T, et al. Pharmacological treatments in gambling disorder: a qualitative review. BioMed Res Int. 2014;537306. Accessed January 18, 2023. https://www.hindawi.com/journals/bmri/2014/537306/
24. Choi SW, Shin YC, Kim DJ, et al. Treatment modalities for patients with gambling disorder. Ann Gen Psychiatry. 2017;16:23. doi:10.1186/s12991-017-0146-2
25. Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol. 2001;16(5):285-289. doi:10.1097/00004850-200109000-00006
26. Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49(11):914-921. doi:10.1016/s0006-3223(01)01079-4
27. Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008;69(5):783-789. doi:10.4088/jcp.v69n0511
28. Kovanen L, Basnet S, Castrén S, et al. A randomised, double-blind, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling. Eur Addict Res. 2016;22(2):70-79. doi:10.1159/000435876
29. Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163(2):303-312. doi:10.1176/appi.ajp.163.2.303
30. Tomko RL, Jones JL, Gilmore AK, et al. N-acetylcysteine: a potential treatment for substance use disorders. Current Psychiatry. 2018;17(6):30-36,41-52,55.
31. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007;62(6):652-657. doi:10.1016/j.biopsych.2006.11.021
32. Grant JE, Odlaug BL, Chamberlain SR, et al. A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psych. 2013;75(1):39-45. doi:10.4088/JCP.13m08411
33. Goslar M, Leibetseder M, Muench HM, et al. Pharmacological treatments for disordered gambling: a meta-analysis. J Gambling Stud. 2019;35(2):415-445. doi:10.1007/s10899-018-09815-y
34. Hedegaard H, Miniño AM, Spencer MR, et al. Drug overdose deaths in the United States, 1999-2020. Centers for Disease Control and Prevention. December 30, 2021. Accessed December 11, 2022. https://stacks.cdc.gov/view/cdc/112340
35. Colfax GN, Santos GM, Das M, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011;68(11):1168-1175. doi:10.1001/archgenpsychiatry.2011.124
36. Coffin PO, Santos GM, Hern J, et al. Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial. JAMA Psychiatry. 2020;77(3):246-255. doi:10.1001/jamapsychiatry.2019.3655
37. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Dependence. 2008;96(3):222-232. doi:10.1016/j.drugalcdep.2008.03.010
38. Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384(2):140-153. doi:10.1056/NEJMoa2020214
39. Jayaram-Lindström N, Hammarberg A, Beck O, et al. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry. 2008;165(11):1442-1448. doi:10.1176/appi.ajp.2008.08020304
40. Schmitz JM, Stotts AL, Rhoades HM, et al. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav. 2001;26(2):167-180. doi:10.1016/s0306-4603(00)00098-8
41. Oslin DW, Pettinati HM, Volpicelli JR, et al. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J Subst Abuse Treat. 1999;16(2):163-167. doi:10.1016/s0740-5472(98)00039-7
42. Johnson BA, Ait-Daoud N, Wang XQ, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry. 2013;70(12):1338-1346. doi:10.1001/jamapsychiatry.2013.2295
43. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Dependence. 2004;75(3):233-240. doi:10.1016/j.drugalcdep.2004.03.008
44. Elkashef A, Kahn R, Yu E, et al. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction. 2012;107(7):1297-1306. doi:10.1111/j.1360-0443.2011.03771.x
45. Hasin DS. US epidemiology of cannabis use and associated problems. Neuropsychopharmacology. 2018;43(1):195-212.
46. Brezing CA, Levin FR. The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology. 2018;43(1):173-194. doi:10.1038/npp.2017.198
47. Bahji A, Meyyappan AC, Hawken ER, et al. Pharmacotherapies for cannabis use disorder: a systematic review and network meta-analysis. Intl J Drug Policy. 2021;97:103295. doi:10.1016/j.drugpo.2021.103295
48. Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012;169(8):805-812. doi:10.1176/appi.ajp.2012.12010055
49. Roten AT, Baker NL, Gray KM. Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial. Addict Behav. 2013;38(3):1788-1791. doi:10.1016/j.addbeh.2012.11.003
50. McClure EA, Sonne SC, Winhusen T, et al. Achieving cannabis cessation—evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials. 2014;39(2):211-223. doi:10.1016/j.cct.2014.08.011
51. Gray KM, Sonne SC, McClure EA, et al. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Dependence. 2017;177:249-257. doi:10.1016/j.drugalcdep.2017.04.020
52. Mason BJ, Crean R, Goodell V, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012;37(7):1689-1698. doi:10.1038/npp.2012.14
